 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
DBTX ... A Cure for Diabetes?!?!?! Diabetex Int'l Corp began operation in Jan 1999 and went as high as 25 3/8. They have made two acquisitions since then. The chart shows a big buying opportunity in September. Now is a great buying opportunity because of what this company offers - Consider closely the following information: Diabetex International Corporation (OTC BB: DBTX) Corporate Overview There are approximately 16 million people in the United States and approximately 120 million people worldwide, who suffer from diabetes. The World Health Organization estimates there will be 300 million diabetics throughout the world by the year 2025. Although diabetes occurs often in older adults, it is one of the most common chronic disorders in the United States and other countries in the world. According to the National Institute of Health about 127,000 children and teenagers, age 19 and younger, are diagnosed with diabetes each year. Diabetes is associated with long-term complications that affect almost every major part of the body. It contributes to blindness, heart disease, strokes, kidney failure, amputations, nerve damage and eventually death. DIABETEX INTERNATIONAL CORPORATION (OTC BB: DBTX) is ready now with revolutionary new technologies that have been tested and approved by the FDA, and which will soon be introduced to the market. With these developments patients will have a more affordable way to treat diabetes, and they will experience improved health and fewer diabetes-related complications. Insurance companies can save money because the cost of these new developments is less than current methods of treatment, and physicians will finally have an effective way to treat their diabetic patients. With DIABETEX INTERNATIONAL's new technology, everyone involved in the treatment of diabetes will benefit. After twelve years of clinical research and the acquisition of 44 patents and FDA approval, DIABETEX INTERNATIONAL is now prepared to introduce and commercialize the following advancements in diabetic care technology: 1) Metabolic (Hepatic) Activation therapy, 2) non-invasive glucose monitoring/diagnosis devices, and 3) a fluid micrometer pumping system. SUMMARY The impact of diabetes on the U.S. economy is enormous. The total annual economic cost of diabetes in 1997 was estimated at $98 billion. This estimate includes $44.1 billion in direct medical treatment and $54 billion for indirect costs attributed to disability and mortality. The costs of medical treatment of diabetes in 1997, according to the American Diabetes Association, represent 5.8 percent of the total health care expenditures in the U.S. The significance of this estimate is underlined by the fact that people diagnosed with diabetes account for only 3.8 percent of the U.S. population. The severity of this estimate is further emphasized by the fact that diabetes-related hospitalizations totaled 13.9 million days in 1997, with an average length of hospitalization being 5.4 days. The toll that diabetes has taken on the U.S. economy is further reflected in the mortality rates of diabetics. Based on death certificate data, diabetes was the underlying cause of death for more than 187,000 people in 1995. In fact, diabetes kills one American every three minutes. These statistics are staggering and illustrate the urgent need for more advanced diabetic care technology. Current treatments are too expensive and insurance companies and patients are hit with astronomical health care costs. Diabetics may spend as much as $100 per day on supplies, including needles, chemical strips, insulin pumps, insulin, etc. Hospital stays and physician bills cause expenses to go much higher. Based on the large number of diabetes-related deaths, current treatments are not effective enough to stop the destruction caused by diabetes. Patients, insurance companies, and physicians will all benefit from new scientific developments that dramatically improve the quality of diagnosis, monitoring, and treatment to combat the effects of diabetes. DIABETEX INTERNATIONAL is uniquely positioned by its technology to take advantage of a tremendous market opportunity. Millions of people in the United States and throughout the world are in desperate need of more advanced diabetic technology in order to live better lives without the threat of severe diabetes-related complications. Their doctors are in need of better methods to treat them. The first company to develop, gain regulatory approval, and market advanced diabetic technology will dominate the market. The window of opportunity is definitely open. DIABETIX INTERNATIONAL now has the capability to take advantage of this need for better technology and is in a position to leverage its new products into a vastly enhanced level of diabetic care for millions of diabetics throughout the world. _________________________ Disclaimer: This business summary may include statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Please be cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties. Actual results may vary materially from those in the forward-looking statements as a result of any number of factors, including competition, capital formation, managerial weaknesses, and other unidentified risk factors that may be present. | ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |